Clinical Research Directory
Browse clinical research sites, groups, and studies.
Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
Sponsor: Invero Pharma, Inc.
Summary
XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management \[TTM\]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).
Official title: XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
1436
Start Date
2026-03
Completion Date
2030-05
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
Xenon
50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
Locations (10)
Hartford Hospital
Hartford, Connecticut, United States
University of Florida
Gainesville, Florida, United States
Memorial Hospital at Gulfport
Gulfport, Mississippi, United States
University Nebraska Medical Center
Omaha, Nebraska, United States
University at Buffalo
Buffalo, New York, United States
Wexner Medical Center, Ohio State University
Columbus, Ohio, United States
Baptist Memorial Hospital, Baptist Clinical Research Institute
Memphis, Tennessee, United States
Houston Methodist Research Institute
Houston, Texas, United States
Aalborg University Hospital
Aalborg, Denmark
University Hospital, Rigshospitalet, Blegdamsvej 9
Copenhagen, Denmark